May 2, 2020
FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian CancerBookmarkGeorge Lundberg, MD
Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.